Abstract Number: 2712 • 2018 ACR/ARHP Annual Meeting
Evaluation of Longitudinal Outcomes in Scleroderma Patients with Negative Immunofluorescent Anti-Nuclear Antibodies
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by inflammation, fibrosis, and vasculopathy. Historical data indicates approximately 90% of patients with SSc test positive…Abstract Number: 2578 • 2017 ACR/ARHP Annual Meeting
RAB4A Protects from Antinuclear Antibody Production and Nephritis in the Pristane-Induced Model of SLE
Background/Purpose: Systematic lupus erythematosus (SLE) is a multisystem chronic inflammatory disease characterized by circulating antinuclear autoantibodies and dysfunction of B cells, T cells, and dendritic…Abstract Number: 43 • 2017 ACR/ARHP Annual Meeting
Regulation of TLR7 Signalling By UBE2L3 Dependent Linear Ubiquitination Explains Dimethyl Fumarate Suppression of Autoreactive B Cell Development in SLE
Background/Purpose: A single risk haplotype spanning UBE2L3 is strongly associated with SLE and multiple autoimmune diseases. The E2 ubiquitin-conjugating enzyme UBE2L3 regulates TNFα and CD40…Abstract Number: 198 • 2017 ACR/ARHP Annual Meeting
The Impact of Electronic Consults (E-Consults) on Positive ANA Referrals in a Veteran Population
Background/Purpose: Referrals to rheumatology for positive ANA in the absence of clinical signs and symptoms is a common practice, which may lead to unnecessary resource…Abstract Number: 476 • 2017 ACR/ARHP Annual Meeting
Novel Interaction between Anti-Citrulline Monoclonal Antibodies and Apoptotic Cells Is Mediated through Citrullinated Nuclear Antigens
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) display broad cross-reactivities and target proteins including a-enolase, filaggrin, vimentin, fibrinogen, and histones. However, every monoclonal ACPA has a distinct…Abstract Number: 559 • 2017 ACR/ARHP Annual Meeting
Performance of Multiple Platforms for Autoantibody Testing in Sjogren’s Syndrome
Background/Purpose: The research classification and clinical diagnosis of SjšgrenÕs syndrome (SS) relies heavily on the detection of autoantibodies against Ro/SSA and La/SSB, particularly in the…Abstract Number: 673 • 2017 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products Distinguish Systemic Lupus Erythematosus from Other Diseases Among Patients with High Antinuclear Antibody Titers and Normal Complement
Background/Purpose: Patients are often referred to the rheumatologist because of elevated anti-nuclear antibody (ANA) titers. We sought to evaluate the association of cell bound complement…Abstract Number: 700 • 2017 ACR/ARHP Annual Meeting
Variability in Method of Testing for Antinuclear Antibodies (ANA): A Survey of Participants in the College of American Pathologist’s (CAP) Proficiency Testing Program
Background/Purpose: A 2010 American College of Rheumatology position paper designated indirect immunofluorescence assay (IFA) on HEp-2 cells the “gold standard” for ANA testing and that…Abstract Number: 1097 • 2017 ACR/ARHP Annual Meeting
Investigating Opportunities for Cost Conscious Care: A Review of Physician Practice in Ordering Anti-Nuclear Antibody Testing at an Academic Community Hospital
Background/Purpose: More than 94,000 ANA tests are performed each year resulting in an estimated cost of 2.24 million dollars annually. The American College of Rheumatology…Abstract Number: 1047 • 2016 ACR/ARHP Annual Meeting
Negative Results of Antinuclear Antibody (ANA) Testing in Clinical Trials of Systemic Lupus Erythematosus (SLE) May be Due to Assay Variability
Background/Purpose: SLE clinical trials typically require that patients have either a positive ANA serology at a central laboratory during screening or have prior positive…Abstract Number: 1049 • 2016 ACR/ARHP Annual Meeting
High Titer ANA Not Necessarily a Valid Criterion for Lupus – Proposal of a Modification to the Criteria for Classification of SLE
Background/Purpose: A positive ANA test is one of ACR Revised Criteria for Classification of SLE, as well as the SLICC classification. The ANA test provides…Abstract Number: 1346 • 2016 ACR/ARHP Annual Meeting
Factors That Influence Therapy in Patients with Undifferentiated Connective Tissue Disease
Background/Purpose: To compare clinical and immunological characteristics in patients with undifferentiated connective tissue disease (UCTD) treated with hydroxycholoroquine (HCQ) in a large academic clinical practice.…Abstract Number: 1769 • 2016 ACR/ARHP Annual Meeting
Fatigue in Anti-Nuclear Antibody Positive Individuals with Insufficient Criteria to Diagnose a Systemic Autoimmune Rheumatic Disease
Background/Purpose: Fatigue is a common symptom of Systemic Autoimmune Rheumatic Disease (SARD) and has been proposed to result from the elaboration of pro-inflammatory factors in…Abstract Number: 1874 • 2016 ACR/ARHP Annual Meeting
Low Rate of Progression in Cases of Isolated Raynaud’s Phenomenon Screened By Nailfold Videocapillaroscopy and Antinuclear Antibody Status Supports Negative Predictive Value of These Tests
Background/Purpose: Raynaud’s phenomenon is common but can progress to definite connective tissue disease. We have observed long term follow up of an unselected consecutive…Abstract Number: 2147 • 2016 ACR/ARHP Annual Meeting
Lack of Pro-Inflammatory Cyto/Chemokines in ANA+ Individuals with Insufficient Criteria for a Diagnosis of Systemic Autoimmune Rheumatic Disease
Background/Purpose: Patients with Systemic Autoimmune Rheumatic Disease (SARD) often have a prolonged pre-clinical phase during which they are anti-nuclear antibody (ANA) positive but lack clinical…